|
Synonyms: pozelimab-bbfg | REGN-3918 | REGN3918 | Veopoz®
pozelimab is an approved drug (FDA (2023))
Compound class:
Antibody
Comment: Pozelimab (REGN-3918) targets the terminal complement component C5 [1]. It is designed to inhibit complement pathway activation and complement-mediated inflammatory tissue damage.
|
Classification  |
|
| Compound class | Antibody |
| Approved drug? | Yes (FDA (2023)) |
| International Nonproprietary Names |
|
| INN number | INN |
| 10945 | pozelimab |
| Synonyms |
| pozelimab-bbfg | REGN-3918 | REGN3918 | Veopoz® |
| Database Links |
|
| Specialist databases | |
| IMGT/mAb-DB | 898 |
| Other databases | |
| GtoPdb PubChem SID | 485206021 |
| Search PubMed clinical trials | pozelimab |
| Search PubMed titles | pozelimab |
| Search PubMed titles/abstracts | pozelimab |
